Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic pathway signatures predict the risk of progression and recurrence in well-differentiated pancreatic neuroendocrine tumors.

Journal of surgical oncology - 1 Oct 2024

Mederos Michael A, Court Colin M, Dipardo Benjamin J, Pisegna Joseph R, Dawson David W, Joe Hines O, Donahue Timothy R, Graeber Thomas G, Girgis Mark D, Tomlinson James S

Abstract excerpt

BACKGROUND: Pancreatic neuroendocrine tumors (pNETs) are genomically diverse tumors. The management of newly diagnosed well-differentiated pNETs is limited by a lack of sensitivity of existing biomarkers for prognostication. Our goal was to investigate the potential utility of genetic markers as a predictor of progression-free survival (PFS) and recurrence-free survival (RFS). METHODS: Whole-exome sequencing of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exome Sequencing

Share to Follow-Up Studies

Share to Neoplasm Recurrence, Local

Share to Neuroendocrine Tumors

Share to Pancreatic Neoplasms

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 39155697
DOI: 10.1002/jso.27830
PMCID: PMC11654900

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic pathway signatures predict the risk of progression and recurrence in well-differentiated pancreatic neuroendocrine tumors.PMID 39155697Read ↗

Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine TumorsSemantic proximity Read ↗

Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges.Semantic proximity Read ↗

Single-cell sequencing reveals the heterogeneity of pancreatic neuroendocrine tumors under genomic instability and histological gradingSemantic proximity Read ↗

Identification of new candidate genes and signalling pathways associated with the development of neuroendocrine pancreatic tumours based on next generation sequencing data.Semantic proximity Read ↗

Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.Semantic proximity Read ↗

Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms.Semantic proximity Read ↗

Clinicopathological and molecular determinants of pancreatic neuroendocrine tumors: toward precision risk stratification.Semantic proximity Read ↗

Integrated genomics and transcriptomics reveal key events in pancreatic neuroendocrine neoplasm.Semantic proximity Read ↗

Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancerSemantic proximity Read ↗

Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: An Analysis of 904 Patients with 7882 Person-Years of Follow-UpSemantic proximity Read ↗

Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis.Semantic proximity Read ↗

The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumoursSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.